Search Press releases

2 Oct 2020

Disposals of own shares

Read More
2 Oct 2020

Changes in UCB's Board of Directors

Read More
25 Sep 2020

Disposals of own shares

Read More
22 Sep 2020

UCB Achieves Important Regulatory Milestone for Bimekizumab

Read More
11 Sep 2020

Disposals of own shares

Read More
9 Sep 2020

Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

Read More

Stay up-to-date on the latest news and information from UCB